Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Caroline Armstrong

Internal Medicine Petersburg, WV Doctor of Osteopathy

NPI 1265758585 CMS profile 330197

65 Hospital Dr, Ste 102, Petersburg, WV 26847

Open in the dashboard

General payments

$4,481

291 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Caroline Armstrong of Petersburg, WV is reported in the CMS Open Payments database as having received $4,481 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $585 36
2024 General $635 37
2023 General $734 44
2022 General $884 68
2021 General $651 42
2020 General $461 30
2019 General $531 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caroline Armstrong
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Caroline Armstrong were reported at $585. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Caroline Armstrong Internal Medicine median Middle half National median
2019 $531 $159 $48–$570 $163
2020 $461 $119 $33–$402 $114
2021 $651 $135 $37–$521 $132
2022 $884 $141 $42–$496 $149
2023 $734 $149 $45–$519 $160
2024 $635 $154 $47–$537 $164
2025 $585 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $698 51 payments
  2. AstraZeneca Pharmaceuticals LP $535 32 payments
  3. Lilly USA, LLC $409 26 payments
  4. Amgen Inc. $358 25 payments
  5. AbbVie, Inc. $341 25 payments
  6. Janssen Pharmaceuticals, Inc $273 17 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $253 17 payments
  8. E.R. Squibb & Sons, L.L.C. $243 15 payments
  9. Novartis Pharmaceuticals Corporation $233 14 payments
  10. Amarin Pharma Inc. $221 13 payments
  11. Other $919 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,475 290 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $667 49 payments
  2. RYBELSUS $610 44 payments
  3. FARXIGA $330 18 payments
  4. XARELTO $273 17 payments
  5. JARDIANCE $231 14 payments
  6. ELIQUIS $226 14 payments
  7. Vascepa $221 13 payments
  8. Repatha $194 13 payments
  9. Otezla $187 14 payments
  10. TRADJENTA $163 12 payments
  11. Other $3,276 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 113 drugs

Part D claims

5,154

Median for Internal Medicine: 777

Drug cost

$526,453

Median for Internal Medicine: $73,373

Branded share of claims

19.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 74 $108,927
Mounjaro Tirzepatide Brand 35 $62,113
Eliquis Apixaban Brand 56 $49,808
Tresiba Flextouch U-200 Insulin Degludec Brand 32 $37,756
Xarelto Rivaroxaban Brand 26 $35,456
Jardiance Empagliflozin Brand 32 $34,244
Trulicity Dulaglutide Brand 32 $32,868
Farxiga Dapagliflozin Propanediol Brand 19 $28,438
Januvia Sitagliptin Phosphate Brand 15 $24,563
Tresiba Flextouch U-100 Insulin Degludec Brand 21 $11,241

The 10 drugs with the highest cost, of 113 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$83,359

Of which drugs: $171

Medicare patients

240

Average age 77

Services billed

2,554

141 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 44%
Ischemic heart disease 36%
Chronic kidney disease 36%
COPD 33%
Depression 32%
Heart failure 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 15 52 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $71
$71 — —
Ozempic
  • Novo Nordisk Inc $71
$71 74 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $64
$64 56 —
XARELTO
  • Janssen Pharmaceuticals, Inc $59
$59 26 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $21
  • Lilly USA, LLC $18
$38 32 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record